Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Herbalife Sales Soar, But Firm Confronts Renewed Scrutiny

This article was originally published in The Tan Sheet

Executive Summary

CEO William Johnson says the firm had “another record performance of double-digit growth while under the constant and unrelenting attack” by activist investor William Ackman. Herbalife executives have met with Sen. Edward Markey’s staff and say they have answered the questions he asked in a January letter.

You may also be interested in...



Herbalife Pushes To Counter Pyramid Scheme Narrative

The multilevel marketer of weight-management shakes and other nutritionals says its independent distributor network, far from being a pyramid scheme, in fact is essential in helping people lose weight and adopt healthy lifestyles, according to Herbalife executives.

US FDA Connects Dots For Drug Manufacturers’ Responses To CRLs With Draft Guidance

CRLs FDA submits in response to ANDAs increased most years since FY 2015, though FY 2020 total likely will be lower than two previous years. A 2019 CRL interrupted GSK's plans to market first mouth spray nicotine replacement therapy in US.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel